Loading…
Based on limited metadata, the FDA issued a warning letter to Samchundang Pharm Co., Ltd., a pharmaceutical manufacturer, on May 13, 2020. Without access to the full letter text or detailed subject line, the specific nature of the violations cannot be determined from the available information. The warning letter addresses drug products under FDA jurisdiction, though the particular manufacturing, quality, or compliance issues involved are not specified in the metadata provided. To understand the full scope and details of the regulatory concerns, the complete warning letter would need to be reviewed.